Skip to main content
. 1999 Jul 15;104(2):173–180. doi: 10.1172/JCI6909

Figure 4.

Figure 4

(a) Boosting of HLA-A*0201 restricted influenza MP-reactive T cells after MP-pulsed DCs. MP-reactive T cells were quantified using an ELISPOT assay. HLA-A*0201 restricted gag peptide served as control. Results are shown as the number of SFCs per 2 × 105 PBMCs, at baseline and 30 days after the injection of control DCs, MP-pulsed DCs, or MP alone without DCs. SEM for all measurements was <20 %. (b) Kinetics of boosting of MP-reactive T cells in a representative subject (D6). MP-reactive T cells were quantified using an ELISPOT assay. HLA-A*0201 restricted gag peptide served as control. For each assay, graded doses of PBMCs (25 × 103 to 2 × 105 cells per well) were incubated with 10 μM influenza MP. Results are shown as the number of SFCs per 2 × 105 PBMCs per well, at various time points. (c) CD8+ nature of the MP-reactive T cells in the ELISPOT assay. The presence of MP-reactive T cells in unseparated PBMCs was compared with that after CD4 and CD8 depletion by panning. Data are from subject D1.